ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2019

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin.

Ioannis Avgerinos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.